Clinical Trial Update: A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 1/Phase 2 study evaluating LBL-007 in combination with tislelizumab plus bevacizumab and a fluoropyrimidine versus be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• LBL-007
• Tislelizumab (tislelizumab)
• fluoropyrimidine (fluoropyrimidine)

Snippet

Sponsor: BeiGene | Conditions: Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING